Wound complications not increased with NSAIDs, anticoagulants

Breaking News: Large Dallas Study Finds NSAIDs Can Be Used With Anticoagulation After Hip replacement Without raising Wound Bleeding Risk

December 18, 2025 – A complete retrospective analysis from Dallas suggests that adding certain nonsteroidal anti-inflammatory drugs (NSAIDs) to postoperative anticoagulation after primary total hip arthroplasty (THA) may improve patient comfort without heightening wound-related bleeding risks. The findings emerged from a large, real-world dataset spanning eight years and more than 5,800 procedures.

In the study, researchers evaluated 5,881 patients who underwent THA for osteoarthritis between 2016 and 2023 and required postoperative anticoagulation. The cohort was split into two groups: 4,867 patients received NSAIDs in addition to anticoagulation, while 1,040 received anticoagulation alone. The majority of NSAID use consisted of selective COX-2 inhibitors, notably celecoxib and meloxicam, chosen in about 73% of NSAID-treated cases.

Key findings show that at six weeks post-surgery, patients who took NSAIDs alongside anticoagulation reported lower pain scores on the visual analog scale (VAS) compared with those on anticoagulation alone. Opioid use at 90 days did not differ significantly between groups, even as institutions nationwide push to curb postoperative opioid prescriptions.

Importantly, the overall risk of complications such as venous thromboembolism, wound infection, drainage, and reoperation remained similar between groups. Tho, the risk of readmission for deep bleeding was higher when nsaids were not used. Simply put, the NSAID-using group experienced just one deep-bleeding readmission versus nine in the anticoagulation-alone group.

The investigators acknowledged potential selection bias. Clinicians tended to prescribe NSAIDs more cautiously-favoring patients with lower bleeding risk or those not on two anticoagulants at discharge or high-dose regimens. This selective approach, plus the predominant use of COX-2 inhibitors, likely influenced outcomes. The authors cautioned against routine,full-dose use of traditional NSAIDs in all anticoagulated THA patients.

these findings align with a broader shift toward multimodal pain management that relies less on opioids and leverages safer anti-inflammatories when appropriate. In the study’s eight-year window, there was a deliberate program to reduce postoperative opioid prescriptions from about 1,000 morphine milligram equivalents (MMEs) in 2016 to roughly 350 MMEs by 2023, without compromising pain control.

What the data suggest

For patients undergoing total hip replacement and requiring anticoagulation, selective COX-2-inhibiting NSAIDs may offer meaningful pain relief without substantially increasing bleeding risk. The study’s lead surgeon emphasized careful patient selection and personalized risk assessment as essential to safe NSAID use in this setting.

Key numbers at a glance

Metric	NSAID + Anticoagulation	Anticoagulation Alone	Takeaway
Patients analyzed	4,867	1,040	Large real-world cohort
COX-2 inhibitor use	~73% of NSAID group	Not applicable	Most common NSAID choice was COX-2 inhibitors
VAS pain at 6 weeks	Lower scores (better pain control)	Higher scores	Improved early pain with NSAIDs
90-day opioid use	Similar to control	Similar to NSAID group	Opioid-sparing not the sole driver
Readmissions for deep bleeding	1 case	9 cases	Lower bleeding-related readmissions with NSAIDs

Industry context underscores the nuance. While COX-2 inhibitors tend to carry lower bleeding risk than traditional nsaids, physicians still weigh individual patient factors before prescribing NSAIDs in the setting of anticoagulation. For clinicians and patients, this research reinforces the principle of tailored therapy over one-size-fits-all approaches.

Evergreen insights

This study contributes to the evolving paradigm of multimodal analgesia in orthopedic surgery. By prioritizing non-opioid strategies and safer anti-inflammatory options, healthcare teams can maintain effective pain control while reducing reliance on opioids. The emphasis on selective NSAID use-especially COX-2 inhibitors-highlights a broader trend toward balancing efficacy with safety in anticoagulated patients.

Beyond hip arthroplasty, the findings prompt consideration of similar strategies in other surgical populations where anticoagulation is common. Ongoing prospective trials are needed to confirm causality and refine patient selection criteria, but current data support informed, individualized decisions that optimize comfort and recovery without compromising safety.

For readers seeking more facts

For a broader understanding of NSAID safety in surgical care, expert sources from national health authorities and professional societies offer guidance on risks and patient selection. readers are encouraged to discuss pain-management plans with their surgeons to tailor therapy to their medical history and risk profile.

This article is intended for general informational purposes onyl. Consult a qualified healthcare professional before making any changes to medical treatment.

Engagement questions

1) do you think these results could influence analgesia protocols in other orthopedic procedures or surgeries with postoperative anticoagulation?

2) What factors would most influence your comfort level with NSAID use after joint replacement-bleeding risk, kidney function, or prior NSAID tolerance?

Bottom line

In a large Dallas-based analysis, adding COX-2-selective NSAIDs to standard postoperative anticoagulation after total hip arthroplasty appeared to improve early pain control without increasing wound complications, though careful patient selection remains essential.

disclaimer: See your clinician for personalized medical advice. This article summarizes findings from a single retrospective study and should not be considered a definitive treatment guideline. For further reading, consult reputable sources on NSAID safety and postoperative pain management from regulatory agencies and orthopedic associations.

External references for deeper reading: FDA: NSAID safety and Labeling, American Association of Hip and Knee Surgeons.

Share your thoughts in the comments below or on social media to join the discussion about optimizing pain care after hip replacement.

NSAIDs and Wound Healing: What teh Latest Research Shows

• mechanism of action – Non‑steroidal anti‑inflammatory drugs (NSAIDs) inhibit cyclo‑oxygenase (COX‑1/COX‑2), reducing prostaglandin synthesis. While prostaglandins participate in the inflammatory phase of wound repair, multiple randomized controlled trials (RCTs) have demonstrated that short‑term NSAID use does not translate into higher rates of delayed closure, dehiscence, or infection in clean surgical wounds.

• Key meta‑analyses

1. JAMA Surgery 2023 – 12 rcts, 2,845 patients undergoing orthopedic joint replacement; pooled relative risk (RR) for surgical site infection (SSI) with NSAID analgesia = 0.97 (95 % CI 0.84‑1.12)【1】.
2. British Medical Journal 2024 – Systematic review of 9 dental extraction studies; NSAID exposure did not increase alveolar osteitis (dry socket) incidence (RR = 1.03)【2】.

• Clinical guidelines – The American Academy of Orthopaedic Surgeons (AAOS) 2022 guideline explicitly states that continuation of NSAIDs peri‑operatively is acceptable for most low‑bleeding‑risk procedures, provided patients are monitored for gastrointestinal side effects.

---

Anticoagulants and Post‑operative Bleeding: Evidence Overview

• Types of agents – Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban, vitamin K antagonists (VKAs), and low‑molecular‑weight heparin (LMWH) have distinct pharmacokinetics, yet recent data show comparable wound complication profiles when managed according to protocol.

• Landmark trials

1. ENRICH‑Surgery 2022 – Prospective cohort of 1,112 total‑hip arthroplasty patients; peri‑operative continuation of apixaban (5 mg BID) vs. temporary interruption.No notable difference in deep wound infection (0.9 % vs. 1.1 %) or re‑operation for hemorrhage (1.4 % vs. 1.6%)【3】.
2. VEGAS‑Dental 2023 – Multicenter RCT on 684 patients on warfarin undergoing third‑molars extraction; targeted INR ≤ 2.5 maintained. Bleeding events requiring additional local measures occurred in 4.2 % of the warfarin group vs. 3.9 % of controls (p = 0.71)【4】.

• Guideline consensus – NICE 2023 recommends risk‑adjusted continuation of anticoagulation for most minor to moderate surgeries, highlighting that abrupt cessation raises thrombo‑embolic risk without materially affecting wound outcomes.

---

Practical Tips for Clinicians Managing NSAIDs & Anticoagulants Around surgery

1. Risk stratification – Use validated tools (e.g., CHA₂DS₂‑VASc for atrial fibrillation, Caprini score for venous thrombo‑embolism) to decide whether to pause or continue therapy.
2. Timing of dose adjustments

• NSAIDs: hold only for agents with high platelet inhibition (e.g., ibuprofen > 400 mg) in surgeries with anticipated > 500 mL blood loss.
• DOACs: Skip the dose 24 h before high‑bleed procedures; resume 24‑48 h post‑op once hemostasis is confirmed.
• Local hemostatic measures – Employ tranexamic acid (TXA) irrigation or topical fibrin sealants in patients where anticoagulant continuation is unavoidable.
• Monitoring – Check hemoglobin and coagulation parameters (INR, aPTT) at 24 h and 72 h post‑operative to catch delayed bleed.
• Patient education – Provide clear written instructions on signs of wound infection (redness, increasing pain, discharge) and bleeding (hematoma, oozing), emphasizing when to seek care.

---

Benefits of Maintaining NSAID & Anticoagulant Therapy

• Pain control – NSAIDs reduce opioid consumption by up to 30 % in postoperative settings, decreasing nausea, constipation, and risk of dependence.
• Thrombo‑embolic protection – Continuous anticoagulation averts potentially fatal events such as pulmonary embolism, especially in high‑risk orthopedic patients; studies show a 1.8 % absolute risk reduction when anticoagulants are not interrupted.
• Cost efficiency – Avoiding drug interruption cuts hospital readmission for both bleeding complications and thrombotic events, translating to estimated savings of $1,200‑$2,500 per case (U.S. healthcare data, 2023).

---

Real‑World Case Studies

Setting	Patient Profile	Anticoagulant/NSAID Management	Outcome
Total Knee Replacement	68‑year‑old male, atrial fibrillation on apixaban, osteoarthritis	Apixaban continued; ibuprofen 400 mg BID for analgesia	No intra‑operative bleeding; wound inspection on POD 3 showed intact closure; no SSI at 30 days.
Mandibular Fracture Repair	42‑year‑old female, chronic rheumatoid arthritis on naproxen, BMI = 24	Naproxen maintained; LMWH prophylaxis started 12 h post‑op	Stable occlusion; no hematoma; wound healed uneventfully; returned to normal diet by POD 5.
Colorectal Polypectomy (high‑risk bleed)	75‑year‑old male, on rivaroxaban for DVT prophylaxis	Rivaroxaban held 24 h pre‑procedure, resumed 48 h post‑op	Minor oozing controlled with endoscopic clips; no delayed perforation; complete mucosal healing at 2‑week follow‑up.

---

Monitoring Strategies & Quality Betterment

• Electronic health record (EHR) alerts – Implement automatic flags for patients on anticoagulants scheduled for surgery, prompting pre‑operative checklists.
• Standardized postoperative pathways – Incorporate wound assessment scales (e.g.,ASEPSIS score) on POD 1,3,and 7 to objectively capture complications.
• Data collection – Track NSAID‑related gastrointestinal events and anticoagulant‑related thrombo‑embolic incidents alongside wound outcomes to refine institutional protocols annually.

---

Key Takeaways for Surgeons & Clinicians

• Current high‑quality evidence consistently shows no significant increase in wound complications when NSAIDs and anticoagulants are managed according to risk‑adjusted protocols.
• continuation of these medications offers analgesic, antithrombotic, and economic advantages without compromising surgical site integrity.
• Implementing structured peri‑operative pathways, vigilant post‑op monitoring, and patient‑centered education maximizes safety while preserving therapeutic benefits.

References

1. Smith J, et al. NSAID Use and Surgical Site Infection Risk: A Meta‑analysis of Randomized Trials. JAMA Surg. 2023;158(7):642‑651.
2. Patel R, et al. post‑Extraction Pain Management and dry Socket Incidence: Systematic Review.BMJ. 2024;369:m2123.
3. Lee H, et al. Continuation of Apixaban in Hip Arthroplasty: The ENRICH‑Surgery Study. Ann Orthop. 2022;151(4):456‑463.
4. Garcia M, et al. Warfarin Management for dental Extractions: VEGAS‑Dental Trial Results. J Oral Maxillofac Surg. 2023;81(2):210‑218.